roman-sinichkin-shutterstock-com-drugs-
Roman Sinichkin / Shutterstock.com
17 March 2016Americas

FTC demands corrections in GSK, Teva pay-for-delay ruling

The US Federal Trade Commission (FTC) has urged a federal appeals court to correct errors in a judgment from a Pennsylvania court that found the plaintiff in a pay-for-delay case had failed to prove that the agreement breached US competition law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 February 2016   The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.
Americas
29 June 2015   The US Court of Appeals for the Third Circuit has ruled that so-called ‘pay-for-delay’ settlements do not need to involve cash payments to be considered anticompetitive.
Americas
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

More on this story

Americas
23 February 2016   The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.
Americas
29 June 2015   The US Court of Appeals for the Third Circuit has ruled that so-called ‘pay-for-delay’ settlements do not need to involve cash payments to be considered anticompetitive.
Americas
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

More on this story

Americas
23 February 2016   The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.
Americas
29 June 2015   The US Court of Appeals for the Third Circuit has ruled that so-called ‘pay-for-delay’ settlements do not need to involve cash payments to be considered anticompetitive.
Americas
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.